You are leaving our website

or Decline

Our Financial Highlights for 2022

These are the primary measures used by management to monitor business performance, against both short-term budgets and forecasts and longer-term strategic plans.

To view in detail view our 2022 Annual Report

currently counter number sum counter number

See-through revenue*

currently counter number sum counter number

GM%: (Overall)

currently counter number sum counter number

Underlaying EBITDA

currently counter number sum counter number

Underlying Profit Before Tax

currently counter number sum counter number

Underlying Basic EPS**

currently counter number sum counter number

Dividend per share

currently counter number sum counter number

Free Cash Flow*

currently counter number sum counter number

Leverage

currently counter number sum counter number

Net Debt

1 These measures constitute Alternative Performance Measures (‘APMs’), as defined in note 31 to the Financial Statements.

2 Leverage is defined as: Adjusted net debt/enlarged Group EBITDA, calculated using pro forma EBITDA on a trailing 12-month basis for acquired entities, in line with our banking covenants.

3 Basis points

Five Year Summary
Year ended 31 December 2018 £mYear ended 31 December 2019 £mYear ended 31 December 2020 £mYear ended 31 December 2021 £mYear ended 31 December 2022 £m
Revenue118.2135.6129.8163.2167.4
Operating profit before non-underlying items28.937.436.845.635.7
Non-underlying operating items(5.3)(1.8)(20.5)(24.0)(24.6)
Operating profit23.735.616.321.611.1
Profit before tax before non-underlying items28.132.933.542.230.3
Profit before tax after non-underlying items22.831.113.018.25.2
Intangible assets335.2328.7412.9413.8422.1
Tangible assets7.611.615.94.85.6
Current assets58.765.077.281.0105.5
Current liabilities91.724.230.240.647.0
Equity252.2274.2281.0282.5288.2
Average shares in issue (millions)497.2520.7531.1535.3539.5
Shares in issue at period end (millions)518.2529.4532.9538.2540.0
Earnings per share – basic (p)3.694.801.511.370.17
Earnings per share – adjusted underlying basic (p)4.545.095.116.394.28

* Non-IFRS alternative performance measures (see note 31). See-through revenue includes all sales from Nizoral as if they had been invoiced by Alliance as principal. For statutory accounting purposes the product margin on Nizoral sales made on an agency basis is included within Revenue, in line with IFRS 15.